Clinical trials: Atopic Skin
Dermatitis, Atopic
A Study of Ustekinumab (STELARA®) in Adult Japanese Participants With Severe Atopic Dermatitis
The purpose of this study is to assess the safety and effectiveness of 2 doses of ustekinumab compared with placebo (inactive medication) in adult Japanese participants with severe atopic dermatitis.
- Trial name
- NCT01945086
- Testing
- Ustekinumab, Concomitant topical medications for atopic dermatitis
- Where
- 13 sites in Japan
- Volunteers
- 79 people
- Sponsor
- Janssen Pharmaceutical K.K.
Moderate-to-Severe Atopic Dermatitis
Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis
The main purpose of the study was to assess the efficacy and safety of nemolizumab after a 16-week treatment period in adult and adolescent subjects with moderate-to-severe atopic dermatitis (AD) not adequately controlled with…
- Trial name
- NCT03989349
- Testing
- Nemolizumab
- Where
- 138 sites in United States, Belgium and 9 more
- Volunteers
- 787 people
- Sponsor
- Galderma R&D
Atopic Dermatitis
An Open Label, Safety Study to Assess the Potential for Adrenal Suppression.
An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Treatment with DSXS in Patients with Atopic Dermatitis
- Trial name
- NCT02932891
- Testing
- DSXS topical
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Dermatitis
Clinical Investigation on the Efficacy and Safety of Relizema Ecofoam
The scope of this open label clinical trial is to evaluate and confirm the performance of Relizema ecofoam in the improvement of the dermatitis severity.
- Trial name
- NCT05001139
- Testing
- Relizema ecofoam
- Where
- Italy
- Volunteers
- 13 people
- Sponsor
- Relife S.r.l.
Atopic Dermatitis
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Assess the efficacy of several subcutaneous doses of nemolizumab in moderate-to-severe atopic dermatitis (AD) subjects with severe pruritus receiving TCS, who were not adequately controlled with topical treatments.
- Trial name
- NCT03100344
- Testing
- Nemolizumab
- Where
- 67 sites in United States, Australia and 4 more
- Volunteers
- 226 people
- Sponsor
- Galderma R&D
Atopic Dermatitis, Eczema
A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) For Treatment of Atopic Dermatitis
This trial will be a double-blind, randomized, placebo-controlled, safety, tolerability and efficacy trial of SAN007 (5% East Indian sandalwood oil in a cream formulation) treatment regimen when administered daily for up to 28…
- Trial name
- NCT02871479
- Testing
- SAN007 5% cream, SAN007 10% cream
- Where
- 5 sites in United States
- Volunteers
- 71 people
- Sponsor
- Santalis Pharmaceuticals, Inc.
Pruritus, Prurigo Nodularis
Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch)
Study of the long term safety of serlopitant for the treatment of pruritus in adults.
- Conditions
- Pruritus, Prurigo Nodularis, Atopic Dermatitis, Psoriasis
- Trial name
- NCT03540160
- Testing
- 5 mg Serlopitant Tablets
- Where
- 85 sites in United States, Austria and 2 more
- Volunteers
- 558 people
- Sponsor
- Vyne Therapeutics Inc.
Atopic Dermatitis
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ASB17061 Capsules in Adult Subjects With Atopic Dermatitis
The purpose of this research study is to gather scientific information about the effectiveness of the study drug, ASB17061 capsules, when compared to placebo in adult subjects with atopic dermatitis.
- Trial name
- NCT01756898
- Testing
- 5 mg ASB17061, 10 mg ASB17061, 20 mg ASB17061
- Where
- 40 sites in United States
- Volunteers
- 370 people
- Sponsor
- Daiichi Sankyo
Atopic Dermatitis
Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis
This is an open-label, single arm study of 52 weeks duration. The study will assess the safety and efficacy of lebrikizumab in adolescent participants (≥12 to <18 years weighing ≥40 kilograms) with moderate-to-severe atopic…
- Trial name
- ADore (NCT04250350)
- Testing
- Lebrikizumab
- Where
- 70 sites in United States, Australia and 2 more
- Volunteers
- 206 people
- Sponsor
- Eli Lilly and Company
Dermatitis, Atopic Dermatitis
Efficacy and Safety Study of Apremilast in Subjects With Moderate to Severe Atopic Dermatitis
A study to evaluate the efficacy and safety of apremilast (CC-10004) in subjects with moderate to severe atopic dermatitis
- Trial name
- NCT02087943
- Testing
- Apremilast
- Where
- 31 sites in United States, Canada and 1 more
- Volunteers
- 191 people
- Sponsor
- Amgen
Treatment-resistant Pruritus Associated With Atopic Dermatitis
Proof of Concept of VLY-686 in Subjects With Treatment-Resistant Pruritus Associated With Atopic Dermatitis
This is randomized, double-blind, placebo-controlled study to test whether VLY-686 can reduce chronic pruritus in subjects with treatment-resistant pruritus associated with atopic dermatitis in comparison with placebo.
- Trial name
- NCT02004041
- Testing
- VLY-686
- Where
- 5 sites in Germany
- Volunteers
- 69 people
- Sponsor
- Vanda Pharmaceuticals
Atopic Dermatitis Eczema, Atopic Dermatitis
Trends in the Epidemiology and Treatment of Atopic Dermatitis in the United Kingdom (UK)
Atopic dermatitis (AD), commonly called eczema, is one of the most frequently occurring skin conditions. It is estimated to affect around one fifth of children in developed countries and is also becoming increasingly common in…
- Conditions
- Atopic Dermatitis Eczema, Atopic Dermatitis, Eczema
- Trial name
- NCT03823794
- Testing
- No intervention
- Where
- United Kingdom
- Volunteers
- 148,166 people, healthy volunteers welcome
- Sponsor
- Momentum Data
Dermatitis, Atopic
Tofacitinib Ointment For Atopic Dermatitis (Atopic Eczema)
The study is being conducted to evaluate the efficacy, safety and tolerability of 2% tofacitinib ointment (20 mg/g) BID (twice daily) in subjects with mild to moderate atopic dermatitis compared to placebo (vehicle) BID for 4…
- Trial name
- NCT02001181
- Testing
- Tofacitinib ointment 20mg/g
- Where
- 5 sites in Canada
- Volunteers
- 69 people
- Sponsor
- Pfizer
Dermatitis, Atopic
Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
This is a randomized, double-blind, placebo-controlled, parallel-group study to confirm the efficacy and safety of Dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis (AD).
- Trial name
- SOLO 2 (NCT02277769)
- Testing
- Dupilumab
- Where
- 93 sites in United States, Canada and 9 more
- Volunteers
- 708 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis
A Study of ATI-502 Topical Solution for the Treatment of Atopic Dermatitis
This is an open label, multicenter study designed to evaluate the safety and tolerability of ATI-502 Topical Solution in male and female subjects with moderate or severe atopic dermatitis (AD).
- Trial name
- NCT03585296
- Testing
- ATI-502
- Where
- 6 sites in United States
- Volunteers
- 22 people
- Sponsor
- Aclaris Therapeutics, Inc.
Healthy Volunteers
Study to Access the Relative Bioavailability of Subcutaneous Dose of Nemolizumab When Administered Via Auto-Injector Versus Dual-Chamber Syringe
This study was to compare the rate and extent of absorption of a single dose of nemolizumab administered with auto-injectors [AI] (test) versus dual-chamber syringes [DCS] (reference) under controlled conditions in healthy adult…
- Trial name
- NCT05405985
- Testing
- Nemolizumab
- Where
- 2 sites in United States
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Atopic Dermatitis
A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis
The purpose of this trial is to test different doses of the trial medicine (LEO 138559) and see how well they work and how safe they are at treating moderate to severe atopic dermatitis in adults.
- Trial name
- NCT05923099
- Testing
- LEO 138559
- Where
- 73 sites in United States, Canada and 9 more
- Volunteers
- 262 people
- Sponsor
- LEO Pharma
Atopic Dermatitis
Effect of OC000459 on Moderate to Severe Atopic Dermatitis
The purpose of this study is to determine whether OC000459 is in reducing disease severity and preventing flares in people with moderate to severe atopic dermatitis (AD).
- Trial name
- NCT02002208
- Testing
- OC000459
- Where
- United Kingdom
- Volunteers
- 142 people
- Sponsor
- Atopix Therapeutics, Ltd.
Atopic Dermatitis
A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
The primary objective of this study is to describe the safety and tolerability of rocatinlimab in adolescents with moderate-to-severe AD.
- Trial name
- ROCKET-Orbit (NCT05633355)
- Testing
- Rocatinlimab
- Where
- 77 sites in United States, Argentina and 7 more
- Volunteers
- 187 people
- Sponsor
- Amgen
Atopic Dermatitis
Cutivate Lotion HPA Axis Pediatric Study
A multi-center, open-label, Phase IV, unblinded study using Cutivate (fluticasone propionate, 0.05%)lotion and it's possible effects on the HPA axis of infants diagnosed with atopic dermatitis.
- Trial name
- NCT00546000
- Testing
- Fluticasone propionate 0.05% lotion
- Where
- 10 sites in United States
- Volunteers
- 56 people
- Sponsor
- Fougera Pharmaceuticals Inc.